Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective
Crossref DOI link: https://doi.org/10.1371/journal.pone.0172731
Published Online: 2017-03-01
Update policy: https://doi.org/10.1371/journal.pone.corrections_policy
Clarke, Caroline S. https://orcid.org/0000-0002-4676-1257
Hunter, Rachael M.
Shemilt, Ian
Serra-Sastre, Victoria
Version of Record valid from 2017-03-01
